What is Vivoo?
Vivoo is at the forefront of at-home diagnostics, offering a suite of urine analysis tests designed to provide users with personalized health insights and actionable advice. Their product line addresses key wellness areas including hydration, fertility, and general well-being, making health monitoring accessible and convenient. By leveraging user health metrics and a dedicated app, Vivoo empowers individuals, particularly women focused on fertility and overall health, to proactively manage their well-being through scientific data and expert guidance.
How much funding has Vivoo raised?
Vivoo has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2021): $6M with participation from 500 Global, Halogen Ventures, Revo Capital, Global Ventures, ONCE Ventures, and Draper Associates
Key Investors in Vivoo
500 Global
500 Global is a venture capital firm that invests in companies across the globe, focusing on early-stage ventures.
Halogen Ventures
Halogen Ventures is an early-stage venture capital fund that invests in consumer technology companies led by women, providing strategic guidance for growth.
Revo Capital
Revo Capital is a venture capital firm that invests in innovative, early-stage B2B and B2C technology ventures, primarily in Turkey, Eastern Europe, and the Baltics.
What's next for Vivoo?
With the recent strategic investment, Vivoo is poised for accelerated growth and market expansion. The substantial capital injection will likely fuel further research and development into new diagnostic tests, enhance their technological platform, and broaden their market reach. This funding round signals a strong belief in Vivoo's mission to democratize health insights and positions the company to further solidify its standing in the competitive digital health and wellness sector. Future developments may include expanding their test offerings and forging strategic partnerships to integrate their insights into broader healthcare ecosystems.
See full Vivoo company page
